Back

Cardiac metabolic alterations as a novel therapeutic target in doxorubicin toxicity

26 January 2026 (17:40 - 17:50)
Organised by: Logo
Seminar Presentation Part of: YIA posters session Heart Failure Delegate Premium access HFA Winter Research Meeting 2026 Heart Failure Association (HFA)

14 More presentations in this session

Presentation thumbnail
Class IIa HDACs Inhibition reverses diastolic dysfunction and Increase Energy Expenditure in a murine HFpEF model
Abstract Slides
Presentation thumbnail
The early metabolic cardiac targets of Empagliflozin during the development of heart failure, independent of SGLT2 inhibition
Abstract Slides
Presentation thumbnail
BET proteins link epigenetic remodeling to impaired autophagy in HFpEF
Abstract Slides
Presentation thumbnail
SDF-1/CXCR4 signaling promotes atrial fibrillation in heart failure with preserved ejection fraction
Abstract Slides
Presentation thumbnail
Unexpected concentric cardiac remodeling induced by selective in vivo cleavage of titin springs in a genetic mouse model.
Abstract Slides

Access the full session

Session thumbnail
YIA posters session

The Event

Event poster

HFA Winter Research Meeting 2026

26 January 2026 17:40 CET
You may be interested in
thumbnail
Congress Presentation
Mitochondrial dynamics and myocardial metabolism alterations during anthracycline-cardiotoxicity
22 May 2023
thumbnail
Congress Session
Emerging insights in cardio-oncology: biomarkers, cardiotoxicity, and protective therapies
20 May 2025
thumbnail
Congress Presentation
Protosappanin a protects DOX-induced myocardial injury and cardiac dysfunction by targeting ACSL4/FTH1 axis-dependent ferroptosis
30 August 2024
thumbnail
Congress Presentation
New target for chemotherapy-induced cardiac dysfunction
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources